1-3 of 3
Moazah Iftikhar
Close
Sort by
Journal Articles

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Kristen McCullough, Omer Karrar, Moazah Iftikhar, Maymona Abdelmagid, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Mrinal M. Patnaik, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat
Journal: Blood
Blood (2023) 142 (Supplement 1): 5925.
https://doi.org/10.1182/blood-2023-182326
Published: 2023
Journal Articles

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

Naseema Gangat, Omer Karrar, Maymona Abdelmagid, Moazah Iftikhar, Kaaren K. Reichard, Natasha Szuber, Ayalew Tefferi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1815.
https://doi.org/10.1182/blood-2023-179596
Published: 2023
Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Omer Karrar, Moazah Iftikhar, Kristen McCullough, Isla Johnson, Maymona Abdelmagid, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Mrinal M. Patnaik, Animesh D. Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat
Journal: Blood
Blood (2023) 142 (Supplement 1): 591.
https://doi.org/10.1182/blood-2023-178837
Published: 2023